Nonalcoholic Steatohepatitis

Seminars in Liver Disease

Volumn 24, Issue 1, 2004, Pages 3-20

  Brunt, Elizabeth M ^a,b  

^a SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^b Saint Louis University   (United States)

Author keywords

Insulin resistance; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Obesity

Indexed keywords

ALCOHOL; AMIODARONE; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; ESTROGEN; HEXESTROL BIS(2 DIETHYLAMINOETHYL) ETHER; METHOTREXATE; TAMOXIFEN;

ADULT; CHILD; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER PARENCHYMA; LIVER TOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; CARCINOMA, HEPATOCELLULAR; CHILD; FATTY LIVER; FATTY LIVER, ALCOHOLIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLIC SYNDROME X; PREVALENCE;

EID: 1942454793     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-823098     Document Type: Review

References (129)

1. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202-1219
3. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002;34:255-262
4. Dixon JB, O'Brien PE, Bhatal PS. A wider view on diagnostic criteria of nonalcoholic steatohepatitis (reply). Gastroenterology 2002;122:841-842
5. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16
6. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438
7. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-816
8. Nasrallah SM, Wills CE, Galambos JT. Hepatic morphology in obesity. Dig Dis Sci 1981;26:325-327
9. Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1349-1355
10. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995;104:23-31
11. Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver - a follow-up study. Hepatology 1995;22:1714-1719
12. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26
13. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419
14. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657
15. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003;124:248-250
16. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100
17. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001;48:206-211
18. Farrell GC. Is bacterial ash the flash that ignites NASH? Gut 2001;48:148-149
19. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome - prevalence and determinants of a "bright" liver echopattern. Ital J Gastroenterol Hepatol 1997;29:351-356
20. Bellentani S, Saccicio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med 2000;132:112-117
21. Bellentani S, Tiribelli C. The spectrum of liver disease in the general population: lesson from the Dionysos study. J Hepatol 2001;35:531-537
22. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-750
23. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79
24. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-9
25. Expert panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001;285:2486-2497
26. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967
27. Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36:227-242
28. Yu AS, Keefe EB. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? (editorial). Am J Gastroenterol 2003;98:955-956
29. Clinical Practice Committee AGA. AGA medical position statement: evaluation of liver chemistry tests. Gastroenterology 2003;123:1364-1366
30. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292
31. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002;17:1136-1143
32. Hilden M, Christoffersen P, Juhl E, Dalgaard JB. Liver histology in a "normal" population - examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977;12:593-597
33. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-1110
34. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614
35. Youssef WI, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 2002;13:17-30
36. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-923
37. Roberts EA. Steatohepatitis in children. Best Pract Res Clin Gastroenterol 2002;16:749-765
38. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669
39. Bacon BR, Farahvash MJ, Janney CG, Neuschwandertetri BA. Nonalcoholic steatohepatitis - an expanded clinical entity. Gastroenterology 1994;107:1103-1109
40. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41
41. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002;22:185-194
42. Garcia-Monzon C, Fernandez-Bermejo M. A wider view of diagnostic criteria of nonalcoholic steatohepatitis (letter to the editor). Gastroenterology 2002;122:840-841
43. Garcia-Monzon C, Martin-Perez E, Lo Iacono O, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716-724
44. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231
45. Neuschwander-Tetri BA. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2002;4:31-36
46. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195-199
47. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-1517
48. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999;18:353-358
49. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455
50. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850
51. Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002;35:367-372
52. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002;35:373-379
53. Youssef WI, McCullough AJ. Steatohepatitis in obese individuals (review). Best Pract Res Clin Gastroenterol 2002;16:733-747
54. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis following 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-1017
55. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Interim results of a pilot study demonstrating the early effects of the PPAR-g ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003;38:434-440
56. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-894
57. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525
58. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Semin Liver Dis 2001;21:57-69
59. Day CP, Saksena S. Nonalcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002;17: S377-S384
60. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:663-678
61. Lebovitz HE. The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl 2003;134:18-27
62. Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-744
63. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37:206-213
64. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001;21:81-88
65. Angulo P, Lindor KD. Treatment of non-alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16:797-810
66. O'Brien PE, Dixon JB. The extent of the problem of obesity. Am J Surg 2002;184:4S-8S
67. Korner J, Leibel RL. To eat or not to eat - how the gut talks to the brain. N EnglJ Med 2003;349:926-928
68. McCullough AJ, Falck-Ytter Y. Body composition and hepatic steatosis as precursors for fibrotic liver disease. Hepatology 1999;29:1328-1330
69. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003;14:137-145
70. Prins JB. Adipose tissue as an endocrine organ. Best Pract Res Clin Endocrinol Metab 2002;16:639-651
71. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin exprssion from human adipose tissue. Relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 2003;52:1779-1785
72. Stumvoll M. Thiazolidinediones - some recent developments. Expert Opin Investig Drugs 2003;12:1179-1187
73. Das UN. Is metabolic syndrome X an inflammatory condition? (Review). Exp Biol Med (Maywood) 2002;227:989-997
74. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100
75. Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003;38:244-251
76. Ludwig J, McGill DB, Lindor KD. Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997;12:398-403
77. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594-598
78. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-1062
79. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987;82:650-654
80. Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis 2002;6:399-420
81. Brunt EM, Tiniakos DG. Pathology of steatohepatitis (review). Best Pract Res Clin Gastroenterol 2002;16:691-707
82. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998;15:246-258
83. Garg A, Misra A. Hepatic steatosis, insulin resistance and adipose tissue disorders (editorial). J Clin Endocrinol Metab 2002;87:3019-3022
84. Ishak KG. Light microscopic morphology of viral hepatitis. Am J Clin Pathol 1976;65:787-827
85. Natori S, Rust C, Stadheim LM, et al. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 2001;34:248-253
86. Ziol M, Tepper M, Lohez M, et al. Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J Hepatol 2001;34:254-260
87. Canbay A, Tamir P, Torok NJ, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-663
88. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-443
89. Nanki T, Koike R, Miyasaka N. Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis (letter to editor). Am J Gastroenterol 1999;94:3379
90. Dourakis SP, Sevastinaos VA, Kaliopi P. Acute severe steatohepatitis related to prednisolone therapy (letter to editor). Am J Gastroenterol 2002;97:1074-1075
91. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002;97:2058-2062
92. Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steathepatitis with other forms of chronic liver disease. Mod Pathol 2003;16:49-56
93. Brunt EM, Tiniakos DG. Steatosis, steatohepatitis: review of effects on chronic hepatitis C. Current Hepatitis Reports 2002;1:38-44
94. Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol 2002;16:767-781
95. Ong JP, Younossi ZM, Speer C, et al. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001;21:266-271
96. Washington K, Wright K, Shyr Y, et al. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol 2000;31:822-828
97. Cortez-Pinto H, Baptista A, Camilo ME, de Moura MC. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis. Hepatogastroenterol 2001;48:87-90
98. Denk H, Stumptner C, Zadoukal K. Mallory bodies revisited. J Hepatol 2000;32:689-702
99. Ludwig J, McGill DB, Lindor KD. Nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997;12:398-403
100. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474
101. Stumptner C, Fuchsbichler A, Heid H, Zatloukal K, Denk H. Mallory body - a disease-associated type of sequestosome. Hepatology 2002;35:1053-1062
102. Savas MC, Koruk M, Pirim I, et al. Serum ubiquitin levels in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2003;50:738-741
103. Teli MR, Day CP, Burt AD, Bennett MJ, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995;346:987-990
104. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999;31:430-434
105. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192
106. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318
107. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999;30:847-850
108. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999;31:421-429
109. Chitturi S, Weltman M, Farrell GC, et al. HFE Mutations, hepatic iron, and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002;36:142-149
110. Cortez-Pinto H, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis - clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172-179
111. Abdelmalek M, Angulo P, Jorgensen RA, Sylvestre PB, Lindor K. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001;96:2711-2717
112. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis - a pilot study. Hepatology 1996;23:1464-1467
113. Andersen T, Gluud C, Franzmann M-B, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-229
114. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362
115. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123
116. Dixon JB, Bhatal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100
117. Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: Risk factors for liver fibrosis. Hepatol Res 2002;24:429-438
118. Evans CDJ, Oien KA, MacSween RNM, Mills PR. Nonalcoholic steatohepatitis: a common cause of advanced liver injury? J Clin Pathol 2002;55:689-692
119. Brunt EM. Grading and staging the histopathologcial lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000;31:241-246
120. Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J Clin Gastroenterol 1995;20:127-130
121. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-373
122. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002;37:154-160
123. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-427
124. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638
125. Nair S, Mason A, Eason J, Loss G, Perillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150-155
126. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-1354
127. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-1493
128. Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites. Diabetes Care 2001;24:843-849
129. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001;61:5016-5023